Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.32 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.32 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.32 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GRM8 | O00222 | 1/20 | 0.32 |
| ▸ | GRM6 | O15303 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | MTOR | P42345 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | KDM1A | O60341 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2306584 | 1.00 | MAPK1 (0.33) | MAPK1CHRM2CHRM1CHRM3GRM2 | |
| SCHEMBL25240305 | 0.89 | GRM4 (0.33) | MAPK1CHRM2CHRM1CHRM3GRM2 | |
| SCHEMBL21064068 | 0.88 | GAA (0.32) | MAPK1 | |
| SCHEMBL18361345 | 0.86 | GAA (0.31) | — | |
| SCHEMBL22722858 | 0.86 | GAA (0.31) | — | |
| SCHEMBL28201308 | 0.85 | CHRM2 (0.39) | MAPK1CHRM2CHRM1CHRM3GRM2 | |
| SCHEMBL2312894 | 0.84 | MAPK1 (0.34) | MAPK1 | |
| SCHEMBL28240411 | 0.81 | CHRM2 (0.32) | CHRM2CHRM1CHRM3KDM1A | |
| SCHEMBL25241773 | 0.81 | MAPK1 (0.34) | MAPK1CHRM2CHRM1CHRM3KDM1A | |
| Formic Acid SCHEMBL27651219 | 0.81 | MAPK1 (0.31) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768889-A | Novel CDK9 kinase inhibitor and preparation method and application thereof | 厦门大学 | 2023-09-19 | — | — | CN | claimed |
| CN-113321650-A | 3-substituent-5- (substituted aryl) -7-azaindole derivative and application thereof | 厦门大学 | 2021-08-31 | — | — | CN | claimed |
| US-12503452-B2 | Antimicrobial compounds and methods | CURZA GLOBAL, LLC (US) | 2025-12-23 | — | — | US | disclosed |
| WO-2024044552-A1 | VHH ANTIBODY DOTA CONJUGATES | Abdera Therapeutics Inc. (US) | 2024-02-29 | — | — | WO | disclosed |
| CN-116768889-A | Novel CDK9 kinase inhibitor and preparation method and application thereof | 厦门大学 | 2023-09-19 | — | — | CN | disclosed |
| US-20230159491-A1 | Antimicrobial Compounds and Methods | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-05-25 | — | — | US | disclosed |
| CN-113493398-B | Preparation method of N-Boc-trans-cyclohexanediamine | 中车长春轨道客车股份有限公司 | 2023-04-14 | — | — | CN | disclosed |
| CN-113321650-B | 3-substituent-5- (substituted aryl) -7-azaindole derivative and application thereof | 厦门大学 | 2022-04-12 | — | — | CN | disclosed |
| CN-113924292-A | Antimicrobial compounds and methods | 库扎环球有限责任公司 | 2022-01-11 | — | — | CN | disclosed |
| CN-111646978-B | N2-substituted alkoxy aromatic ring-2-aminopyrimidine derivatives and application thereof | 浙江大学 | 2021-12-21 | — | — | CN | disclosed |
| EP-3911644-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS | Curza Global LLC (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-1450811-A2 | 2-ARYL PYRROLOPYRIMIDINES FOR A1 AND A3 RECEPTORS | Osi Pharmaceuticals, Inc. (US) | 2004-09-01 | — | — | EP | disclosed |
| US-20040029837-A1 | Oxazine derivatives | EVOTEC AG (DE) | 2004-02-12 | — | — | US | disclosed |
| EP-1347980-A1 | COMPOUNDS SPECIFIC TO ADENOSINE-A1,-A2A, AND- A3-RECEPTOR AND USES THEREOF | OSI Pharmaceuticals, Inc. (US) | 2003-10-01 | — | — | EP | disclosed |
| WO-2003048120-A2 | 2-ARYL PYRROLOGPYRIMIDINES FOR A1 AND A3 RECEPTORS | OSI PHARMACEUTICALS, INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| EP-1317511-A1 | OXAZINE DERIVATIVES | Evotec BioSystems AG (DE) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002057267-A1 | COMPOUNDS SPECIFIC TO ADENOSINE A1, A2A, AND A3 RECEPTOR AND USES THEREOF | OSI PHARMACEUTICALS, INC. (US) | 2002-07-25 | — | — | WO | disclosed |
| EP-1213328-A1 | Oxazine derivatives | Evotec OAI AG (DE) | 2002-06-12 | — | — | EP | disclosed |
| WO-2002020670-A1 | OXAZINE DERIVATIVES | EVOTEC OAI AG (DE) | 2002-03-14 | — | — | WO | disclosed |
| CN-1165815-A | Phenol compound and process for preparing the same | TANABE SEIYAKU CO (JP) | 1997-11-26 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159491-A1 | Antimicrobial Compounds and Methods | MPO, NISCH, RPN2 | MAPK1 2873/4885CHRM2 4855/4885CHRM1 4819/4885 |
| US-20040029837-A1 | Oxazine derivatives | OXA1L, HELZ, IKZF2 | MAPK1 4751/4885CHRM2 3548/4885CHRM1 2357/4885 |
| US-12503452-B2 | Antimicrobial compounds and methods | MPO, NISCH, RPN2 | MAPK1 2873/4885CHRM2 4855/4885CHRM1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.